• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PEP 笛自我护理与常规护理在早期 COVID-19 中的效果:丹麦社区环境中非药物、开放标签、随机对照试验。

Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting.

机构信息

Parker Institute, Copenhagen University Hospital Bispebjerg-Frederiksberg, Frederiksberg, Denmark

University College Diakonissestiftelsen, Bachelor of Science in Nursing Programme, Danish Deaconess Community, Frederiksberg, Denmark.

出版信息

BMJ. 2021 Nov 24;375:e066952. doi: 10.1136/bmj-2021-066952.

DOI:10.1136/bmj-2021-066952
PMID:34819329
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10476062/
Abstract

OBJECTIVE

To determine whether positive expiratory pressure (PEP) by PEP flute self-care is effective in reducing respiratory symptoms among community dwelling adults with SARS-CoV-2 infection and early stage covid-19.

DESIGN

Non-drug, open label, randomised controlled trial.

SETTING

Capital Region and Region Zealand in Denmark from 6 October 2020 to 26 February 2021.

PARTICIPANTS

Community dwelling adults, able to perform self-care, with a new SARS-CoV-2 infection (verified by reverse transcription polymerase chain reaction tests) and symptoms of covid-19.

INTERVENTION

Participants were randomised to use PEP flute self-care in addition to usual care or have usual care only. Randomisation was based on permuted random blocks in a 1:1 ratio, stratified for sex and age (<60 or ≥60 years). The PEP self-care group was instructed to use a PEP flute three times per day during the 30 day intervention.

MAIN OUTCOME MEASURES

Primary outcome was a change in symptom severity from baseline to day 30, as assessed by the self-reported COPD (chronic obstructive pulmonary disease) assessment test (CAT), which was adjusted for baseline values and stratification factors. Participants completed the CAT test questionnaire every day online. Secondary outcomes were self-reported urgent care visits due to covid-19, number of covid-19 related symptoms, and change in self-rated health, all within 30-days' follow-up.

RESULTS

378 participants were assigned to the PEP flute self-care intervention (n=190) or usual care only (n=188). In the PEP self-care group, the median number of days with PEP flute use was 21 days (interquartile range 13-25). For the intention-to-treat population, a group difference was observed in changes from baseline in CAT scores of -1.2 points (95% confidence interval -2.1 to -0.2; P=0.017) in favour of the PEP flute self-care group. At day 30, the PEP flute self-care group also reported less chest tightness, less dyspnoea, more vigour, and higher level of daily activities, but these differences were small, and no consistent effects were seen on the secondary outcomes. No serious adverse events were reported.

CONCLUSIONS

In community dwelling adults with early covid-19, PEP flute self-care had a significant, yet marginal and uncertain clinical effect on respiratory symptom severity, as measured by CAT scores.

TRIAL REGISTRATION

ClinicalTrials.gov NCT04530435.

摘要

目的

确定通过使用 PEP 吹管进行自我护理是否能有效减轻社区感染 SARS-CoV-2 病毒和处于早期新冠阶段的成年人的呼吸道症状。

设计

非药物、开放性标签、随机对照试验。

地点

丹麦首都大区和西兰大区,时间为 2020 年 10 月 6 日至 2021 年 2 月 26 日。

参与者

能够进行自我护理、新感染 SARS-CoV-2(通过逆转录聚合酶链反应检测证实)并有新冠症状的社区居住成年人。

干预

参与者被随机分配到使用 PEP 吹管进行自我护理(附加于常规护理)或仅接受常规护理。随机分配基于按区组随机化的 1:1 比例,按性别和年龄(<60 岁或≥60 岁)分层。PEP 自我护理组被指示在 30 天的干预期间每天使用 PEP 吹管 3 次。

主要结局指标

主要结局是通过自我报告的 COPD(慢性阻塞性肺疾病)评估测试(CAT)评估的症状严重程度从基线到第 30 天的变化,该测试针对基线值和分层因素进行了调整。参与者每天在线完成 CAT 测试问卷。次要结局是 30 天随访内因新冠而紧急就医的自我报告次数、新冠相关症状的数量以及自我评估健康状况的变化。

结果

378 名参与者被分配到 PEP 吹管自我护理干预组(n=190)或仅接受常规护理组(n=188)。在 PEP 自我护理组中,使用 PEP 吹管的中位数天数为 21 天(四分位距 13-25)。对于意向治疗人群,PEP 吹管自我护理组的 CAT 评分从基线变化的组间差异为-1.2 分(95%置信区间-2.1 至-0.2;P=0.017),有利于 PEP 吹管自我护理组。在第 30 天,PEP 吹管自我护理组还报告了较少的胸闷、较少的呼吸困难、更多的活力和更高的日常活动水平,但这些差异较小,次要结局没有一致的效果。没有报告严重不良事件。

结论

在患有早期新冠的社区居住成年人中,PEP 吹管自我护理对 CAT 评分测量的呼吸道症状严重程度具有显著但边际和不确定的临床效果。

试验注册

ClinicalTrials.gov NCT04530435。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/cfea87d42728/mola066952.f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/697e6c25043e/mola066952.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/7d2aefadeb65/mola066952.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/cfea87d42728/mola066952.f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/697e6c25043e/mola066952.f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/7d2aefadeb65/mola066952.f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac8f/10476062/cfea87d42728/mola066952.f3.jpg

相似文献

1
Effect of PEP flute self-care versus usual care in early covid-19: non-drug, open label, randomised controlled trial in a Danish community setting.PEP 笛自我护理与常规护理在早期 COVID-19 中的效果:丹麦社区环境中非药物、开放标签、随机对照试验。
BMJ. 2021 Nov 24;375:e066952. doi: 10.1136/bmj-2021-066952.
2
PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.PEP-CoV 方案:一项预防 COVID-19 早期呼吸道恶化和住院的 PEP 吹管自我护理随机对照试验。
BMJ Open. 2021 Jun 30;11(6):e050582. doi: 10.1136/bmjopen-2021-050582.
3
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.用于评估非住院轻中度 COVID-19 患者肠道微生物组调节的自然史和影响的虚拟化临床研究:一项随机、开放标签、前瞻性研究,平行组研究评估 KB109 对肠道微生物组结构和功能的生理影响:一项随机对照研究方案的结构化总结。
Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0.
4
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
5
Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.羟氯喹用于接触新冠病毒疾病(COVID-19)后成年人暴露者预防严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)感染的暴露后预防效果:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4.
6
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验(SAINT)评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力:一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.
7
ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.羟氯喹用于 COVID-19 传染病的化学预防(PROLIFIC)以预防一线医护人员感染 COVID-19:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 2;21(1):604. doi: 10.1186/s13063-020-04543-4.
8
A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.一项评估静脉注射瑞维鲁单抗对比 COVID-19 重症肺炎、急性肺损伤或急性呼吸窘迫综合征患者最佳支持治疗的疗效和安全性的 III 期开放性标签、随机对照研究:一项随机对照试验研究方案的结构性总结。
Trials. 2020 Jul 13;21(1):639. doi: 10.1186/s13063-020-04548-z.
9
A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.一项针对高风险确诊严重 SARS-CoV-2 疾病患者的随机开放标签 II 期临床试验,比较 SARS-CoV-2 感染后恢复期患者输注血浆与未输注血浆的疗效(RECOVER):一项随机对照试验的研究方案的结构化总结。
Trials. 2020 Oct 6;21(1):828. doi: 10.1186/s13063-020-04735-y.
10
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.吸入用布地奈德治疗早期 COVID-19(STOIC):一项 2 期、开放标签、随机对照试验。
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.

引用本文的文献

1
Evidence-based position paper on physical and rehabilitation medicine professional practice for persons with COVID-19, including post COVID-19 condition: the European PRM position (UEMS PRM Section).基于证据的关于 COVID-19 患者的物理医学与康复医学专业实践的立场文件,包括新冠后状况:欧洲物理医学与康复医学学会(UEMS PRM 分会)的立场。
Eur J Phys Rehabil Med. 2023 Dec;59(6):789-799. doi: 10.23736/S1973-9087.23.08315-6.
2
Clinical standards for diagnosis, treatment and prevention of post-COVID-19 lung disease.临床诊断、治疗和预防新冠后肺部疾病标准。
Int J Tuberc Lung Dis. 2023 Oct 1;27(10):729-741. doi: 10.5588/ijtld.23.0248.
3

本文引用的文献

1
Unmet need for COVID-19 therapies in community settings.社区环境中对新冠病毒治疗的未满足需求。
Lancet Infect Dis. 2021 Nov;21(11):1471. doi: 10.1016/S1473-3099(21)00633-2. Epub 2021 Oct 14.
2
PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.PEP-CoV 方案:一项预防 COVID-19 早期呼吸道恶化和住院的 PEP 吹管自我护理随机对照试验。
BMJ Open. 2021 Jun 30;11(6):e050582. doi: 10.1136/bmjopen-2021-050582.
3
Measuring the impact of covid-19.衡量新冠疫情的影响。
Feasibility and Short-Term SpO/FiO Changes in Hospitalized Adults with COVID-19 Pneumonia after Chest Physiotherapy with Threshold PEP Valve: A Cross-Sectional Study.
阈值PEP阀胸部物理治疗后COVID-19肺炎住院成人的可行性及短期SpO₂/FiO₂变化:一项横断面研究
J Clin Med. 2023 Aug 25;12(17):5544. doi: 10.3390/jcm12175544.
4
SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death.SARS-CoV-2 感染(COVID-19):临床病程、病毒引起的急性呼吸窘迫综合征(ARDS)和死亡原因。
Med Sci (Basel). 2022 Oct 10;10(4):58. doi: 10.3390/medsci10040058.
5
Rehabilitation and COVID-19: update of the rapid living systematic review by Cochrane Rehabilitation Field as of December 31st, 2021.康复与新冠疫情:截至2021年12月31日Cochrane康复领域快速循证综述的更新
Eur J Phys Rehabil Med. 2022 Apr;58(2):328-331. doi: 10.23736/S1973-9087.22.07497-4. Epub 2022 Mar 4.
BMJ. 2021 May 19;373:n1239. doi: 10.1136/bmj.n1239.
4
COVID-19 and acute respiratory failure treated with CPAP.新冠病毒肺炎及采用持续气道正压通气治疗的急性呼吸衰竭
Eur Clin Respir J. 2021 Apr 11;8(1):1910191. doi: 10.1080/20018525.2021.1910191.
5
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.吸入用布地奈德治疗早期 COVID-19(STOIC):一项 2 期、开放标签、随机对照试验。
Lancet Respir Med. 2021 Jul;9(7):763-772. doi: 10.1016/S2213-2600(21)00160-0. Epub 2021 Apr 9.
6
Attributes and predictors of long COVID.长新冠的特征和预测因素。
Nat Med. 2021 Apr;27(4):626-631. doi: 10.1038/s41591-021-01292-y. Epub 2021 Mar 10.
7
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.阿奇霉素用于英国有不良临床病程风险增加人群的疑似 COVID-19 社区治疗(PRINCIPLE):一项随机、对照、开放标签、适应性平台试验。
Lancet. 2021 Mar 20;397(10279):1063-1074. doi: 10.1016/S0140-6736(21)00461-X. Epub 2021 Mar 4.
8
Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.高剂量锌和抗坏血酸补充剂与常规治疗相比对 SARS-CoV-2 感染门诊患者症状持续时间和缓解的影响:COVID A to Z 随机临床试验。
JAMA Netw Open. 2021 Feb 1;4(2):e210369. doi: 10.1001/jamanetworkopen.2021.0369.
9
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial.氟伏沙明对比安慰剂在伴有症状的 COVID-19 门诊患者中的临床恶化:一项随机临床试验。
JAMA. 2020 Dec 8;324(22):2292-2300. doi: 10.1001/jama.2020.22760.
10
COPD assessment test for the evaluation of COVID-19 symptoms.用于评估 COVID-19 症状的 COPD 评估测试。
Thorax. 2021 Feb;76(2):185-187. doi: 10.1136/thoraxjnl-2020-215916. Epub 2020 Nov 4.